CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

Coast News highlights Cancer Survivor and CureMatch CEO Blaise Barrelet’s journey

Coast News highlights Cancer Survivor and CureMatch CEO Blaise Barrelet’s journey
Press

An article appeared in today’s Coast News which chronicles Blaise Barrelet‘s journey from cancer patient to CureMatch CEO, and shares that the CureMatch personalized medicine approach is online and ready. Actionable insights based upon genomics are now available to the best oncologists across the country to quickly match up combination drug treatments using the most in-depth custom curated databases of drugs and cancer mutations available.


New data technology emerges for cancer patients

BY: Christina Macone-Greene

RANCHO SANTA FE: While each person responds to their cancer diagnosis in their own way, one common sensation described by many is a fog-like emotional numbness.

Blaise Barrelet felt this very same sensation following his Chronic Lymphocytic Leukemia (CLL) diagnosis. When the fog lifted, he embarked on his own quest to find the best cancer treatments, which also inspired him to build a company to help other cancer patients.

A resident of Rancho Santa Fe for the last 18 years, Barrelet moved to San Diego 21 years ago. A native of France, Barrelet was instantly drawn to the Ranch’s topography, which he found reminiscent of the French countryside.

Considered a trailblazer in website analytics, Barrelet is regarded for his background in technology. After he founded WebSideStory in 1996, it underwent a successful IPO in 2004. Barrelet is a cancer survivor and described by many as a serial entrepreneur.

Nonetheless, it was his analytical mind that was the driving force in not settling for his oncologist’s recommendation of a chemotherapy protocol in addressing his cancer four years ago.

“So I started doing all my research. Luckily, I found out that one of the top three leaders in research for CLL was right here in San Diego at The Moores Cancer Center. His name is Tom Kipps and he’s really a fantastic guy,” he said.

Barrelet began to recognize the advances for a new protocol in cancer treatments: Personalized medicine by way of a tumor’s molecular profile.

It was this discovery that triggered the creation of CureMatch, Inc., which is headquartered in San Diego. Barrelet is a co-founder, holds the title of chief executive officer and is chairman of the board.

Barrelet explained that the software platform of CureMatch offers a decision support system in assisting oncologists by ranking the combination of cancer drugs based on the molecular profile of a patient’s tumor following a biopsy. He went on to say that once a tumor undergoes DNA sequencing, the next steps are a genetic analysis which ultimately arrives at the data-driven drug combination therapies. A patient’s oncologist can then review the information and arrive at a treatment plan that is individualized and tailored. This is important, Barrelet said, because no two cancers are alike.

According to CureMatch, matched combination therapy has been shown in studies to have higher response and survival rates than traditional chemotherapy or targeted monotherapies.

Barrelet uses the analogy of a sinking boat and how chemo is a “bucket” to empty the water in the vessel. Personalized medicine, however, looks at the gene aberrations which created the holes and analyzes the ways to plug as many of them as possible via combination match therapy.

“We know how to combine these drugs in a way that we actually try to plug every hole that is in the boat. Sometimes we succeed,” he said. “Sometimes we plug maybe 80 percent of the holes. But if you’ve got 20 percent of the holes still, it’s going to take a long time for the boat to sink.”

Barrelet explained that CureMatch is combining drugs based on toxicity, on their interaction, and pathways at the molecular level.

Barrelet is quick to point out how the company’s other highly regarded co-founders are Igor Tsigelny and Razelle Kurzrock.

The company also notes that its technology was originally created and licensed by a multidisciplinary team at UC San Diego Moores Cancer Center and the San Diego Supercomputer Center. It was then developed into a commercial product by CureMatch.

“At CureMatch, we come back with a combination of drugs that are going to be the most impactful in a report,” Barrelet said. “We have an algorithm to find out where we are going to get the most impact. So it’s great information for an oncologist.”

Currently, there are 300 FDA drugs for cancer treatment today. Barrelet said from that number, it’s estimated that there are more than four million possibilities for combination therapy. Additionally, there are roughly 500 more drugs in the FDA pipeline which will vastly increase these possibilities.

“What we’re trying to do is offer oncologists more knowledge,” he said. “There are only 2.5 percent of cancer patients today that get their tumors sequenced. It’s ridiculous, but it’s changing because the price of DNA sequencing is totally going down.”

Barrelet said that CureMatch is giving oncologists insight on what the best treatments are and helping patients by giving them hope.


Thanks again to The Coast News for stopping by and providing the opportunity to share this story of hope through the advances in personalized medicine. If you or a friend, family member, or medical professional are interested in fast tracking the oncology treatment process, contact us today.

View the entire article.

New data technology emerges for cancer patients

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data